

**Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg**

*Ahmedabad, India, October 6, 2025*

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.

Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.

ZDS- Liothyronine tablets will be manufactured at Zydus’ plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

###



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878